In this article, we will be taking a look at the 10 best cancer stocks to buy now.
Global Oncology Market Overview and Drug Shortages
In 2022, the global oncology market was valued at approximately $203.42 billion and is expected to reach over $470.61 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.8% from 2023 to 2032. The market for cancer drugs alone was estimated at $147 billion in 2022 and is forecasted to exceed $300 billion by 2032. In 2020, approximately 19.3 million new cancer cases and about 10 million cancer-related deaths were recorded worldwide. By 2040, new cancer cases are expected to increase by 47%. The U.S. oncology market is a significant segment of the global market. Cancer medicine spending in the U.S. was a large part of the $223 billion spent globally on cancer medicines in 2023.
The picture of oncology is gradually changing, and companies are progressively working on the further discovery of the variants aimed at developing new treatments that can increase the chances of recovery for a wider population of patients. Thus, it is possible to note that the availability and consumption of these new cancer medications differ greatly around the globe. An analysis of clinical trials for oncology conducted in 2022 shows that clinical trial activity is steadily on the rise, 22% higher than in the baseline year of 2018, as reflected by IQVIA. In the last one-year period, a global one percent increment in cancer patients has been observed, and across five years, an overall five percent increase in patients undergoing cancer treatment is quite evident. Future predictions show that cancer medications will cost $375 billion by 2027, while the total global expenditure in the year 2022 will be $196 billion. Currently, the oncology pipeline is growing exceptionally fast with over 2,000 products being in the pipeline. Of these products, 71% are being created by high-growth biopharmaceutical firms of moderate size only. These companies have further scaled up their funding for the advancement of cancer treatment solutions from 51% in 2017. Globally, 237 new active substances for cancer have been launched in the market over the last 20 years and about 115 over the last five years. NAS has flown 78 times in the last five years, and 189 times overall within the last twenty years in the United States.
Thus, the US FDA is thinking of allowing the temporary import of chemotherapy drugs from manufacturers that do not have clearance in the United States due to a shortage of over a dozen cancer medications. This step has been deemed necessary to lessen the burden of paradoxical inflation on the hospitals especially regarding crucial drugs such as cisplatin and carboplatin that are vital in combating cancer. Thus, WHO has identified these drugs as essential in primary health care. Because of such problems, hospitals have had to adjust the usage by lowering the delivered doses and serving the most needy patients. Dr. Abdul Rafeh Naqash of the Stephenson Cancer Center at the University of Oklahoma also affirmed it.
“The lawmakers in the country need to understand that this is a big problem at this point, where unless something changes in the next few weeks, this can lead to a big national emergency from a patient and health care standpoint.”
The shortages of cisplatin and carboplatin stem from a temporary production halt at an Intas Pharmaceuticals facility in India. Dr. Karen Knudsen, CEO of the American Cancer Society, highlighted that these shortages reflect ongoing economic issues in the generic drug market. She also mentioned that the demand for these drugs is expected to rise in the coming years due to an aging population, as older individuals have a higher risk of cancer.
A scientist in a lab researching the biology of a cancer cell.
Our Methodology
Our methodology for identifying the best cancer stocks by sifting through ETFs and online rankings. We compiled an initial list of companies with a market capitalization exceeding $1 billion. From that, we selected the 10 stocks that were the most widely held by hedge funds, as of Q2 2024. The stocks are sorted in ascending order of the number of hedge funds that have positions in them.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
Here is our list of the 10 best cancer stocks to buy now.
10. Novartis AG (NYSE:NVS)
Hedge Fund Holdings: 30
Novartis AG (NYSE:NVS) is a Swiss multinational pharmaceutical company that specializes in innovative drugs across key areas like oncology, rare diseases, neuroscience, and cardio-metabolic conditions. The company has a strong focus on innovation, particularly in oncology, Novartis’s robust late-stage pipeline is set to drive long-term growth, with new drugs expected in critical therapeutic areas. The U.S. accounts for about one-third of its global sales.
A key catalyst for Novartis AG (NYSE:NVS) is its acquisition of MorphoSys AG for €2.7 billion, enhancing its oncology pipeline with pelabresib, a late-stage BET inhibitor for myelofibrosis. Pelabresib has shown promising Phase 3 trial results, meeting its primary endpoint of spleen volume reduction. With regulatory filing expected in the second half of 2024, it could become a groundbreaking first-line treatment for myelofibrosis, creating a new market segment for Novartis.
In Q2 2024, Novartis AG (NYSE:NVS) reported strong financial results, with adjusted earnings of $1.97 per share on $12.51 billion in sales, beating expectations. This marks an increase from $1.73 per share and $13.62 billion in sales the previous year. The core operating income margin neared 40%, reflecting better profitability. Novartis also raised its projected operating income growth to the mid-to high-teens range, signaling confidence in its near-term outlook.
As of Q2 2024, the company had 30 hedge fund holders with Renaissance Technologies being the top holder with a stake worth $266,126,792.
9. AstraZeneca PLC (NASDAQ:AZN)
Hedge Fund Holdings: 49
AstraZeneca PLC (NASDAQ:AZN) is a global biopharmaceutical company that specializes in innovative prescription medicines across various therapeutic areas, with a strong focus on oncology. The company excels in developing and selling drugs for cancer, cardiovascular, renal, metabolism, and respiratory diseases. AstraZeneca’s notable success in oncology which is driven by several blockbuster drugs, has led to sales exceeding $5 billion in a single quarter which highlights the company’s leadership in cancer treatment.
AstraZeneca PLC (NASDAQ:AZN) stands out for its groundbreaking cancer treatments, particularly its flagship drug Tagrisso, which reduces disease progression risk by 84% in Stage 3 lung cancer. The company is also advancing in targeted therapies with innovative CAR-T treatments for liver cancer and new approaches for breast cancer, reinforcing its leadership in the field.
As for its current portfolio, here’s what AstraZeneca PLC (NASDAQ:AZN)’s management shared during the Q2 2024 earnings call:
“As Pascal just highlighted, we have had a very strong start to the year with total revenue increasing 18%. This was driven largely by substantial product sales growth across the portfolio. Alliance revenue also increased by 50% in the first half, mainly driven by an increase in HER2 sales in regions where Daiichi Sankyo recorded revenue. Please turn to the next slide. This is our core P&L. In the first half, total revenue grew 18%, as I just mentioned, and our core product sales gross margin was 82.4%. We’ve previously said that we anticipate a slightly lower core product sales gross margin for the full year versus 2023, and we expect downward pressure in the second half driven by the usual seasonal impact of medicines such as FluMist, as well as increased before supply, which comes at a lower gross margin.”
8. AbbVie Inc. (NYSE:ABBV)
Hedge Fund Holdings: 67
AbbVie Inc. (NYSE:ABBV), a global biopharmaceutical company, develops and sells prescription medications for various health conditions, focusing on chronic autoimmune diseases, oncology, virology, and neurological disorders. The company recently strengthened its oncology presence by acquiring ImmunoGen for $10.1 billion, adding ELAHERE, an ADC approved for platinum-resistant ovarian cancer, to its portfolio. The company’s focus on developing targeted medicines that impede cancer cell reproduction or enable their death through immuno-oncology approaches and tumor antigen targeting is another catalyst for growth. AbbVie’s expansion into solid tumors, which represent over 90% of cancers, presents a significant opportunity for market expansion.
Over the past five years, AbbVie Inc. (NYSE:ABBV) has delivered impressive returns, achieving 129% in total returns and outpacing the S&P 500. This performance was largely driven by Humira’s success and strategic acquisitions like Allergan. AbbVie is trading at nearly 15 times projected 2024 profits, which may seem fully priced for a company facing near-term growth challenges. However, this valuation could be considered reasonable given the company’s strong dividend yield of 3.8% and potential for future growth once the Humira decline stabilizes. CFRA maintains a “buy” rating on AbbVie with a price target of $195. The company also announced the acquisition of Cerevel Therapeutics recently for $8.7 billion, expanding its presence in the neurological disorders space. As of Q2 2024, there were 67 hedge fund holders in the company with Citadel Investment Group being the largest hedge fund with 2,617,800 worth $449,005,056.
AbbVie Inc. (NYSE:ABBV) is making significant progress in its oncology pipeline, particularly in solid tumors. The Phase 2 PICCOLO study showed that Elahere, as a monotherapy for ER alpha-positive, third-line-plus platinum-sensitive ovarian cancer, achieved a 52% objective response rate and an 8.25-month median duration of response. AbbVie plans to submit Teliso-V for accelerated approval for c-Met overexpressing, EGFR wild-type non-small-cell lung cancer, with a decision expected in 2025. Additionally, promising data from the Phase 1 trial of ABBV-400, a next-generation c-Met ADC, has led to its advancement in late-line colorectal cancer.
